ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
ADC Therapeutics has raised $60.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in October 2025.
ADC Therapeutics's investors include AstraZeneca, Redmile Group, TCG Crossover, Deerfield, 4BIO Capital.
ADC Therapeutics is headquartered in Lausanne, Switzerland.
ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
ADC Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ADC Therapeutics — Funding & Investors." VCBacked, October 13, 2025, https://www.vcbacked.co/company/adc-therapeutics. Accessed September 30, 2026.
VCBacked. (2025). ADC Therapeutics — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/adc-therapeutics
{{cite web |title=ADC Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adc-therapeutics |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated